Roughly half this business runs on repair and remodel work that happens whether or not anyone buys a new home this year, and the multiple does not reflect that at all.

Stay with this, and you will know exactly which September data point to watch.

Specialty Retail

The Buckle Inc. (NYSE: BKE) trades near $43 after second-quarter sales increased 4.6% to $319.8 million and comparable sales rose 2.1%. Diluted EPS of $0.87 came in ahead of expectations, while first-half EPS climbed roughly 13% year over year.

Valuation remains modest despite those gains. Buckle trades near 10 times trailing earnings and holds more than $300 million in cash and investments with essentially no traditional financial debt, leaving you with a stronger balance-sheet cushion than the headline multiple suggests.

The company also pays a $1.40 annualized regular dividend, for a yield of around 3.2% at today’s price. Shares remain roughly 30% below their 52-week high even as first-half sales continue moving higher.

The Balance Sheet Leaves Room for Error

Cash and investments represent roughly 15% of Buckle’s current market value, while the company carries no bank borrowings. Your valuation case therefore does not depend entirely on faster retail growth, because liquid financial assets already support a meaningful portion of the equity value.

Fashion Risk Keeps the Multiple Low

Q2 EPS slipped slightly from a year earlier, comparable-sales growth has slowed, and rising operating costs could pressure margins if consumer demand weakens. If you want the roughly 10-times earnings multiple to rerate, Buckle still needs steady merchandising execution alongside its strong balance sheet.

Biotechnology

Arbutus Biopharma Corporation (NASDAQ: ABUS) trades in the high $4s after announcing plans for a modified Dutch auction tender worth up to $230 million. The company expects to offer between $5.00 and $5.75 per share, putting the entire tender range above its recent market price.

If fully used, the program could retire roughly 40 million to 46 million shares, equal to about 20% to 23% of the current share count. That would leave a dramatically smaller equity base if the tender proceeds near its maximum size.

Arbutus can fund the transaction after receiving about $178 million from its Moderna patent settlement, plus $92.6 million in cash and securities at the end of June. The company also retains its hepatitis B pipeline and additional intellectual-property litigation as potential sources of value.

The Buyback Is Large Enough to Reshape the Stock

A $230 million tender equals roughly one-quarter of Arbutus’ current market value, making this far more aggressive than a routine authorization. Your valuation case improves substantially if a smaller share count eventually divides into successful drug or patent assets.

Cash Is Being Exchanged for Biotech Risk

Arbutus remains a clinical-stage company without a traditional earnings base, and the Moderna payment is a one-time windfall. If you tender nothing and stay invested, the remaining pipeline has to justify management spending such a large portion of available cash on repurchases.

Gaming & Digital Entertainment

NetEase Inc. (NASDAQ: NTES) trades near $128.67 after Goldman Sachs and Bernstein raised their price targets following second-quarter results. Gaming revenue increased 9.7% year over year, gross profit climbed 17.5%, and operating profit grew roughly 29% as margins strengthened.

NetEase trades near 13 times forward earnings while holding about $24.7 billion in net cash, roughly 30% of its market value. Strip away that cash, and you are paying considerably less for the gaming and digital businesses themselves.

Cash generation adds another layer, with operating cash flow reaching about $3.5 billion during the first half. Goldman estimates the shares offer roughly a 10% free-cash-flow yield, giving your valuation case support beyond the headline earnings multiple.

Gaming Margins Are Doing the Heavy Lifting

Gaming gross margin reached roughly 76% as established titles and newer releases supported profitability. If operating expenses stay controlled, you get room for earnings to rise even without another major acceleration in revenue.

The Pipeline Still Has to Deliver

One newer title, Sea of Remnants, started more slowly than expected, while Q2 net income fell because of investment losses, impairment charges, and a higher tax rate. NetEase also carries the regulatory and geopolitical risks attached to Chinese ADRs, which can keep its valuation below U.S. gaming peers.

Owens Corning (NYSE: OC)

Owens Corning gives you housing exposure without the homebuilder dependency, which is a genuinely different risk profile than most people realize. The company holds dominant positions in insulation and roofing, and both categories draw heavily from repair and remodel spend rather than new construction, so demand keeps flowing whether or not anyone breaks ground this year.

Aging housing stock generates its own replacement cycle on a schedule nobody has to approve. Management has been guiding steady margin expansion while the stock trades at a multiple that treats the whole business as a pure cyclical. Watch the September housing prints, because mortgage rates drifting lower would pull new construction demand on top of a repair base that never left.

Gap Inc. (NYSE: GAP)

Gap has now posted four consecutive quarters of positive comps under Richard Dickson, and the brand portfolio is finally pulling in the same direction rather than four. Old Navy carries volume, Athleta has stabilized, and the namesake brand has stopped bleeding share.

Margins are up, inventory is clean, and there is over $2 billion in cash sitting on the balance sheet. You are paying single-digit forward earnings with a dividend above 3% while a turnaround that is already working continues to work. Q3 results in late November will confirm whether the back-to-school and early holiday reads hold, and that is the number that matters most.

Elanco Animal Health (NYSE: ELAN)

Elanco has been treated as a broken spinout since separating from Lilly, and the debt load is the honest reason why. What has changed is that deleveraging is tracking to plan while newer companion animal launches take a larger share of the revenue mix each quarter.

Pet health spending has proven more durable than almost any other consumer category, because people cut their own discretionary budgets long before they cut the dog’s medication. You are buying a franchise business at a distressed multiple while the balance sheet repairs itself in the background. The risk is straightforward: if deleveraging slips, the multiple stays where it is.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge